S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:MYLMylan Stock Price, Forecast & News

$16.64
+0.28 (+1.71 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$16.56
Now: $16.64
$16.86
50-Day Range
$15.88
MA: $16.27
$17.00
52-Week Range
$12.75
Now: $16.64
$23.11
Volume5.81 million shs
Average Volume6.65 million shs
Market Capitalization$8.60 billion
P/E Ratio31.40
Dividend YieldN/A
Beta1.53
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Read More
Mylan logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MYL
CUSIP62853010
Phone724-514-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.50 billion
Cash Flow$8.49 per share
Book Value$23.02 per share

Profitability

Net Income$16.80 million

Miscellaneous

Employees35,000
Market Cap$8.60 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$16.64
+0.28 (+1.71 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mylan (NASDAQ:MYL) Frequently Asked Questions

How has Mylan's stock been impacted by COVID-19 (Coronavirus)?

Mylan's stock was trading at $14.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MYL stock has increased by 15.0% and is now trading at $16.64.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Mylan?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Mylan
.

When is Mylan's next earnings date?

Mylan is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Mylan
.

How were Mylan's earnings last quarter?

Mylan NV (NASDAQ:MYL) issued its quarterly earnings results on Thursday, August, 6th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.95 by $0.16. The business earned $2.73 billion during the quarter, compared to analysts' expectations of $2.74 billion. Mylan had a return on equity of 20.43% and a net margin of 2.35%. The business's quarterly revenue was down 4.2% compared to the same quarter last year. During the same period last year, the business posted $1.03 EPS.
View Mylan's earnings history
.

What guidance has Mylan issued on next quarter's earnings?

Mylan issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.5-12 billion, compared to the consensus revenue estimate of $11.62 billion.

What price target have analysts set for MYL?

8 brokers have issued 1 year price targets for Mylan's shares. Their forecasts range from $17.00 to $27.00. On average, they expect Mylan's stock price to reach $20.67 in the next year. This suggests a possible upside of 24.2% from the stock's current price.
View analysts' price targets for Mylan
.

Has Mylan been receiving favorable news coverage?

News stories about MYL stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mylan earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Mylan
.

Are investors shorting Mylan?

Mylan saw a increase in short interest in May. As of May 15th, there was short interest totaling 27,660,000 shares, an increase of 20.5% from the April 30th total of 22,960,000 shares. Based on an average trading volume of 7,886,400 shares, the short-interest ratio is presently 3.5 days. Approximately 5.4% of the shares of the stock are sold short.
View Mylan's Short Interest
.

Who are some of Mylan's key competitors?

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), NVIDIA (NVDA), Cisco Systems (CSCO), Intel (INTC), AbbVie (ABBV) and Starbucks (SBUX).

Who are Mylan's key executives?

Mylan's management team includes the following people:
  • Ms. Heather Bresch, CEO & Exec. Director (Age 50)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 58)
  • Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)
  • Mr. Anthony Mauro, Chief Commercial Officer (Age 46)
  • Mr. Daniel M. Gallagher Jr., Advisor (Age 46)

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Who are Mylan's major shareholders?

Mylan's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pzena Investment Management LLC (3.24%), Bank of New York Mellon Corp (0.95%), Russell Investments Group Ltd. (0.63%), US Bancorp DE (0.56%), Swiss National Bank (0.39%) and Phoenix Holdings Ltd. (0.37%). Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt.
View institutional ownership trends for Mylan
.

Which institutional investors are selling Mylan stock?

MYL stock was sold by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, First Trust Advisors LP, State of Wisconsin Investment Board, Retirement Systems of Alabama, Bank of New York Mellon Corp, Prudential Financial Inc., Robeco Institutional Asset Management B.V., and Jabodon PT Co..
View insider buying and selling activity for Mylan
.

Which institutional investors are buying Mylan stock?

MYL stock was purchased by a variety of institutional investors in the last quarter, including US Bancorp DE, AJO LP, Russell Investments Group Ltd., State of Alaska Department of Revenue, SG Americas Securities LLC, Andra AP fonden, Achmea Investment Management B.V., and RMB Capital Management LLC. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt.
View insider buying and selling activity for Mylan
.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $16.64.

How big of a company is Mylan?

Mylan has a market capitalization of $8.60 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

What is Mylan's official website?

The official website for Mylan is www.mylan.com.

How can I contact Mylan?

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.